NasdaqGM:EYPTPharmaceuticals
EyePoint Pharmaceuticals (EYPT) Is Up 8.4% After Positive Phase 3 Safety Review for DURAVYU
EyePoint Pharmaceuticals recently announced that the independent Data Safety Monitoring Committee completed its second scheduled review of the pivotal Phase 3 trial for DURAVYU, an investigational sustained-release therapy for wet age-related macular degeneration (wet AMD).
This review highlights DURAVYU's potential to offer a differentiated, long-acting treatment option for both wet AMD and diabetic macular edema (DME), addressing therapeutic needs in these growing patient...